Pearl River Capital’s AstraZeneca AZN Stock Holding History

Pearl River Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8,036	Closed	-$801K	–	509
2019 Q4	$801K	Buy	+8,036	New	+$757K	0.3%	91

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pearl River Capital's AZN Position: Q1 2020 in Review

Pearl River Capital sold out of AstraZeneca (AZN) in Q1 2020, closing a stake of 8,036 shares — an estimated $801K sold.

Pearl River Capital first reported a position in AZN in Q4 2019 and held it in 1 quarter. The position peaked at $801K in Q4 2019. 603 funds tracked by Wall St. Rank hold AZN as of Q1 2020.

Pearl River Capital reported no remaining AstraZeneca position as of Q1 2020 after selling out during the quarter.
Pearl River Capital sold 8,036 AstraZeneca shares in Q1 2020, an estimated $801K.
Pearl River Capital first reported a position in AstraZeneca in Q4 2019 and held it in 1 quarter.
Pearl River Capital's AstraZeneca position peaked at $801K in Q4 2019.
603 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2020.

Based on Pearl River Capital's 13F filing for Q1 2020, filed 6 May 2020.